EASD 2025: New frontiers in diabetes care revealed
Annual meeting reveals first EASD guideline on diabetes distress, semaglutide, CagriSema, combination therapies, and CVD advances in diabetes care.
> Read moreAnnual meeting reveals first EASD guideline on diabetes distress, semaglutide, CagriSema, combination therapies, and CVD advances in diabetes care.
> Read moreWhile nerve disease remains a persistent challenge in diabetes care, a new era of multidisciplinary, evidence-based and person-centred approaches is emerging.
> Read moreNerve disease is one of the most common diabetes-related complications, occurring in approximately 1 in 2 people living with the condition.
> Read moreAwareness, capacity-building and accurate data are key to tackling this common and serious complication affecting people with diabetes.
> Read moreThe land of the Alyawarr people in central Australia has become the unlikely ground zero in the global diabetes fight.
> Read moreIn California, where doctors performed more than 82,000 diabetic amputations from 2011 to 2017, people who were black or Latino were more than twice as likely as non-Hispanic whites to undergo amputations related to diabetes, a Kaiser Health News analysis found.
> Read more